JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on September 29, 2004; DOI: 10.1124/jpet.104.076042


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.076042v1
312/2/767    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Desai, A.
Right arrow Articles by Eikenburg, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Desai, A.
Right arrow Articles by Eikenburg, D. C.


Received for publication August 12, 2004.
Revised September 27, 2004.
Accepted for publication September 28, 2004.

Cellular GRK Levels Regulate Sensitivity of the {alpha}2B-Adrenergic Receptor to Undergo Agonist-induced Down-regulation

Aarti Desai 1, Kelly M. Standifer 1, Douglas C. Eikenburg 1*

1 University of Houston

* Address correspondence to: E-mail: deikenburg{at}uh.edu

Abstract

Chronic co-activation of {alpha}2B- and {beta}2-ARs was recently reported to down-regulate the {alpha}2B-AR at a lower threshold EPI concentration compared to when the {alpha}2B-AR alone is activated. This is the result of a modest {beta}2-AR dependent up-regulation of GRK3. In the present study we determined that increasing GRK2 or GRK3 levels, independent of {beta}2-AR activation, decreases the EC50 concentration for agonist-induced down-regulation of the {alpha}2B-AR using NG108 cells with or without over-expression (2-10 fold) of GRK2 or GRK3. In parental NG108 cells, the EC50 concentration of EPI required for down-regulation of the {alpha}2B-AR is 30 µM. A 2-3-fold over-expression of GRK3 in NG108 cells however reduces the EC50 to 0.2 µM (a 150-fold decrease) while a comparable over-expression of GRK2 reduces it to 1 µM (a 30-fold decrease). However, when GRK3 or GRK2 in NG108 cells are overexpressed 8-10-fold, the EC50 concentration (0.02 µM EPI) for {alpha}2B-AR down-regulation is reduced 1000-fold. These data clearly suggest that a modest (2-3 fold) up-regulation of GRK3 is more effective at enhancing the sensitivity of {alpha}2B-AR to down-regulation after exposure to EPI than a modest up-regulation of GRK2, but that both GRK2 and GRK3 are equally effective at inducing {alpha}2B-AR down-regulation when upregulated 8-10 fold. To our knowledge, this is the first report to systematically demonstrate that GRKs, particularly GRK3, play a pivotal role in modulating the agonist EC50 concentration that down-regulates the {alpha}2B-AR and thus adds a new dimension to an already intricate signaling network.


Key words: GRK, alpha-adrenoceptor, down-regulation, epinephrine, norepinephrine, signaling


This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
S. Salim, K. M. Standifer, and D. C. Eikenburg
Extracellular Signal-Regulated Kinase 1/2-Mediated Transcriptional Regulation of G-Protein-Coupled Receptor Kinase 3 Expression in Neuronal Cells
J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 51 - 59.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Salim and D. C. Eikenburg
Role of 90-kDa Heat Shock Protein (Hsp 90) and Protein Degradation in Regulating Neuronal Levels of G Protein-Coupled Receptor Kinase 3
J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 1106 - 1112.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. N. Desai, S. Salim, K. M. Standifer, and D. C. Eikenburg
Involvement of G Protein-Coupled Receptor Kinase (GRK) 3 and GRK2 in Down-Regulation of the {alpha}2B-Adrenoceptor
J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1027 - 1035.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.